Lexicon rises on new Phase II diabetes data; still no partner
This article was originally published in Scrip
Lexicon Pharmaceuticals doesn't have a partner to advance its dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) into Phase III clinical trials, but the company's stock still gained 21.4% to close at $2.89 per share on 1 October based on statistically significant top-line results from a small Phase II trial for the oral diabetes drug LX4211.
You may also be interested in...
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.